Alexey Smolin

7.9k total citations
20 papers, 182 citations indexed

About

Alexey Smolin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Alexey Smolin has authored 20 papers receiving a total of 182 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Alexey Smolin's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Alexey Smolin is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Alexey Smolin collaborates with scholars based in Russia, Japan and United States. Alexey Smolin's co-authors include Niels Reinmuth, Solange Peters, Myung‐Ju Ahn, Vladimir Moiseyenko, Michel M. van den Heuvel, David Vicente, Scott Antonia, Kazuhiko Nakagawa, Alexander Luft and G. Robinet and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Alexey Smolin

13 papers receiving 181 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alexey Smolin Russia	7	165	122	33	31	26	20	182
Patricia Iranzo Spain	7	108 0.7×	66 0.5×	15 0.5×	34 1.1×	25 1.0×	22	158
S. Morris Switzerland	7	243 1.5×	123 1.0×	93 2.8×	19 0.6×	53 2.0×	13	267
Kristiina Ojamaa Estonia	4	91 0.6×	57 0.5×	37 1.1×	22 0.7×	17 0.7×	9	125
Aurelia Alexandru Romania	8	111 0.7×	111 0.9×	12 0.4×	24 0.8×	14 0.5×	24	155
Vanesa Gutiérrez Spain	6	110 0.7×	61 0.5×	52 1.6×	19 0.6×	45 1.7×	13	134
J. Letreut France	5	120 0.7×	134 1.1×	39 1.2×	26 0.8×	34 1.3×	7	164
Jocelyn Booth United States	5	82 0.5×	62 0.5×	82 2.5×	36 1.2×	53 2.0×	11	156
O. Molinier France	9	216 1.3×	247 2.0×	26 0.8×	24 0.8×	39 1.5×	20	296
Benjamin Shum United Kingdom	4	92 0.6×	39 0.3×	12 0.4×	27 0.9×	36 1.4×	6	140
Deepti Venkatraman United States	5	126 0.8×	82 0.7×	8 0.2×	30 1.0×	49 1.9×	10	169

Countries citing papers authored by Alexey Smolin

Since Specialization

Citations

This map shows the geographic impact of Alexey Smolin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexey Smolin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexey Smolin more than expected).

Fields of papers citing papers by Alexey Smolin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexey Smolin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexey Smolin. The network helps show where Alexey Smolin may publish in the future.

Co-authorship network of co-authors of Alexey Smolin

This figure shows the co-authorship network connecting the top 25 collaborators of Alexey Smolin. A scholar is included among the top collaborators of Alexey Smolin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexey Smolin. Alexey Smolin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Лактионов, К. К., et al.. (2024). Current issues of increasing the availability of innovative therapy for the treatment of patients with non-small cell lung cancer within the Russian healthcare system. 78–85.

Leighl, Natasha B., Luis Paz‐Ares, Delvys Rodríguez‐Abreu, et al.. (2023). 65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. Immuno-Oncology Technology. 20. 100537–100537. 8 indexed citations

Zhukova, Lyudmila, et al.. (2023). Clinical significance of MET alterations in non-small cell lung cancer and currently available therapies. Malignant tumours. 13(3). 37–48.

Reck, Martin, Minu K. Srivastava, Heather A. Wakelee, et al.. (2023). IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.. Journal of Clinical Oncology. 41(16_suppl). 8522–8522. 2 indexed citations

Бредер, В. В., Evgeny N. Imyanitov, К. К. Лактионов, et al.. (2022). Resolution on the results of Advisory Board “Searching the effective methods of testing and treating patients with NSCLC caused by <i>NTRK</i> gene fusions“. SHILAP Revista de lepidopterología. 50–56.

Reck, Martin, Tony Mok, Aaron S. Mansfield, et al.. (2022). Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. Journal of Thoracic Oncology. 17(9). 1122–1129. 17 indexed citations

Sands, Jacob, Martin Reck, Alejandro Navarro, et al.. (2022). KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS8606–TPS8606. 6 indexed citations

Çiçin, İrfan, et al.. (2022). ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences. Critical Reviews in Oncology/Hematology. 180. 103847–103847. 6 indexed citations

Smolin, Alexey, et al.. (2021). Potential predictors of the immunotherapy effectiveness. 2(3(5)). 63–69.

10.

Smolin, Alexey, et al.. (2021). The role of immunotherapy in the treatment of extensive small cell lung cancer. 2(2). 40–45.

11.

Reck, Martin, Leora Horn, Tony Mok, et al.. (2021). OA11.06 IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology. 16(3). S128–S128. 1 indexed citations

12.

Liu, Stephen V., Tony Mok, Aaron S. Mansfield, et al.. (2021). VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo). Annals of Oncology. 32(8). 1063–1065. 4 indexed citations

13.

Tryakin, A., Daniil Stroyakovskiy, Anastasia Mochalova, et al.. (2020). Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA trial. SHILAP Revista de lepidopterología. 165–174.

14.

Liu, Stephen V., Leora Horn, Tony Mok, et al.. (2020). 1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer. Annals of Oncology. 31. S1032–S1033. 14 indexed citations

15.

Mochalova, Anastasia, et al.. (2019). Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia. SHILAP Revista de lepidopterología. 104–113. 1 indexed citations

16.

Rizvi, Naiyer A., Byoung Chul Cho, Niels Reinmuth, et al.. (2019). Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.. Journal of Clinical Oncology. 37(15_suppl). 9016–9016. 11 indexed citations

17.

Tryakin, A., Anastasia Mochalova, Andrey Meshcheryakov, et al.. (2019). Ramucirumab in the treatment of refractory metastatic gastric cancer: Results from the RamSelGa trial. Annals of Oncology. 30. v306–v307. 1 indexed citations

18.

Cho, Byoung Chul, Niels Reinmuth, K.H. Lee, et al.. (2019). Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC. Annals of Oncology. 30. ii79–ii80. 7 indexed citations

19.

Rizvi, Naiyer A., Niels Reinmuth, K.H. Lee, et al.. (2018). Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. Annals of Oncology. 29. x40–x41. 74 indexed citations

20.

Савелов, Н. А., et al.. (2014). Immunohistochemistry, Fluorescence in Situ Hybridization, and Reverse Transcription–Polymerase Chain Reaction for the Detection of Anaplastic Lymphoma Kinase Gene Rearrangements in Patients With Non–Small Cell Lung Cancer: Potential Advantages and Methodologic Pitfalls. Archives of Pathology & Laboratory Medicine. 138(6). 794–802. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact